This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has AMN Healthcare Services (AMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Apollo Endosurgery, Inc. (APEN) have performed compared to their sector so far this year.
Apollo Endosurgery, Inc. (APEN) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Apollo Endosurgery, Inc. (APEN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Apollo Endosurgery, Inc. (APEN)? Wall Street Analysts Think 35%
by Zacks Equity Research
The consensus price target hints at a 35.4% upside potential for Apollo Endosurgery, Inc. (APEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Apollo Endosurgery, Inc. (APEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 35.29% and 17.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Apollo Endosurgery, Inc. (APEN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 10.53% and 17.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Apollo Endosurgery, Inc. (APEN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for April 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th
5 ETFs & Stocks to Profit From One-Year High U.S. Inflation
by Sanghamitra Saha
The annual U.S. inflation for the month of November beat expectations and put these ETFs and stocks in focus.
Apollo Endosurgery (APEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apollo Endosurgery (APEN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical (EYES) in Focus: Stock Moves 12.1% Higher
by Zacks Equity Research
Second Sight Medical (EYES) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.
Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
Cogentix Medical (CGNT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
4 Top-Ranked Growth Stocks in MedTech Under $20
by Zacks Equity Research
In the wake of the turbulent political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable picks.